Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

INTRODUCTION: Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Surg Oncol
Main Authors: Bello, Danielle M., Panageas, Katherine S., Hollmann, Travis, Shoushtari, Alexander N., Momtaz, Parisa, Chapman, Paul B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Brady, Mary S., Coit, Daniel G., Ariyan, Charlotte E.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7112166/
https://ncbi.nlm.nih.gov/pubmed/31848819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08099-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares